PMID- 14594341
OWN - NLM
STAT- MEDLINE
DCOM- 20040304
LR  - 20190917
IS  - 0277-0008 (Print)
IS  - 0277-0008 (Linking)
VI  - 23
IP  - 10
DP  - 2003 Oct
TI  - Putting an Ecstasy test kit to the test: harm reduction or harm induction?
PG  - 1238-44
AB  - OBJECTIVE: To evaluate the DanceSafe Complete Adulterant Screening Kit for 
      Ecstasy with regard to its accuracy in identifying 
      3,4-methylenedioxymeth-amphetamine (MDMA) and methylenedioxyamphetamine (MDA) 
      derivatives and its ability to detect certain contaminants. METHODS: In part 1, 
      39 street-grade tablets purported to be MDMA were tested with the Marquis, Mecke, 
      and Simon's reagents provided by the DanceSafe testing kit. The tablets then were 
      submitted to gas chromatography-mass spectrometry for identification of active 
      ingredients. In part II, seven known drugs of abuse were tested with the Marquis, 
      Mecke, and Simon's reagents. These drugs were codeine, dextromethorphan, 
      dihydrocodeine, ketamine, MDMA, morphine, and d-norpropoxyphene. RESULTS: The 
      Marquis, Mecke, and Simon's reagents did not differentiate pure MDMA from 
      adulterated forms. They lacked both sensitivity and specificity for the purpose 
      of MDMA identification when tested by persons unfamiliar with these reagents. 
      Also, experienced toxicologists using this unfamiliar procedure generated 
      false-positive results. CONCLUSIONS: Neither the Marquis, Mecke, nor Simon's 
      reagents should be used by the public for harm reduction purposes. These agents 
      do not help identify pure MDMA tablets. Gas chromatography-mass spectrometry 
      remains the most sensitive and specific testing method for identifying MDMA and 
      its contaminants.
FAU - Murray, Rebecca A
AU  - Murray RA
AD  - Department of Pharmacy Practice, College of Pharmacy, University of Florida, 
      Gainesville, Florida, USA.
FAU - Doering, Paul L
AU  - Doering PL
FAU - Boothby, Lisa A
AU  - Boothby LA
FAU - Merves, Michele L
AU  - Merves ML
FAU - McCusker, Rachel R
AU  - McCusker RR
FAU - Chronister, Chris W
AU  - Chronister CW
FAU - Goldberger, Bruce A
AU  - Goldberger BA
LA  - eng
GR  - T35 HL07489/HL/NHLBI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Pharmacotherapy
JT  - Pharmacotherapy
JID - 8111305
RN  - 0 (Reagent Kits, Diagnostic)
RN  - 0 (Tablets)
RN  - 4764-17-4 (3,4-Methylenedioxyamphetamine)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - 3,4-Methylenedioxyamphetamine/analysis
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*analysis
MH  - *Reagent Kits, Diagnostic
MH  - Reproducibility of Results
MH  - Sensitivity and Specificity
MH  - Substance Abuse Detection/methods
MH  - Tablets
EDAT- 2003/11/05 05:00
MHDA- 2004/03/05 05:00
CRDT- 2003/11/05 05:00
PHST- 2003/11/05 05:00 [pubmed]
PHST- 2004/03/05 05:00 [medline]
PHST- 2003/11/05 05:00 [entrez]
AID - 10.1592/phco.23.12.1238.32704 [doi]
PST - ppublish
SO  - Pharmacotherapy. 2003 Oct;23(10):1238-44. doi: 10.1592/phco.23.12.1238.32704.